• (-)-JQ1: Empowering BET Bromodomain Research with Precision

  2026-07-24

  This article explores the mechanistic rationale and strategic imperatives for integrating (-)-JQ1, the inactive JQ1 stereoisomer, into BET bromodomain and epigenetics research. By synthesizing recent advances in transcriptional regulation, cancer biology, and translational workflows, we provide actionable guidance for researchers seeking to maximize specificity, reproducibility, and data integrity. We frame (-)-JQ1’s unique value within the evolving landscape of targeted epigenetic therapies, spotlighting its role in rigorous experimental design and the translational bridge from bench to potential clinic.

• Reliable MPTP Detection Using the Mitochondrial Permeability

  2026-07-24

  This article addresses practical laboratory challenges in mitochondrial function studies and demonstrates how the Mitochondrial Permeability Transition Pore Assay Kit (SKU K2061) enables reproducible, quantitative detection of MPTP status. Real-world scenarios highlight the kit’s Calcein AM fluorescent probe workflow, validated parameters, and best-practice data interpretation for apoptosis, necrosis, and mitochondrial dysfunction research.

• AO/PI Double Staining: Precision in Translational Cell Death

  2026-07-23

  This thought-leadership article explores the mechanistic and strategic value of the AO/PI Double Staining Kit for translational researchers. It connects the biological rationale behind Acridine Orange and Propidium Iodide staining with practical guidance in the context of advanced organoid models and personalized oncology, drawing on recent peer-reviewed findings and the evolving competitive landscape.

• Adenosine Triphosphate in Mitochondrial Metabolism Research

  2026-07-23

  Adenosine triphosphate (ATP) is indispensable for probing mitochondrial function, energetics, and purinergic signaling in advanced cell models. This guide demystifies ATP's hands-on use for dissecting enzyme regulation and metabolic flux, with workflow enhancements and troubleshooting tips based on the latest research.

• Isoliensinine Modulates TRPV1-AMPK to Attenuate MAFLD Fibros

  2026-07-22

  This study elucidates how isoliensinine from Plumula Nelumbinis ameliorates hepatic fibrosis in metabolic associated fatty liver disease (MAFLD) by restoring lipid droplet metabolism through TRPV1-AMPK activation. These findings highlight a mechanistic link between calcium homeostasis, lipid storage, and anti-fibrotic effects, suggesting potential translational routes for metabolic disease research.

• CB-5083: Applied p97 Inhibitor Workflows in Cancer Models

  2026-07-22

  CB-5083 enables precise disruption of protein homeostasis and potent induction of apoptosis in cancer research, thanks to its selectivity and in vivo efficacy. This guide bridges the latest mechanistic discoveries on p97 and stress granule regulation with optimized experimental workflows and troubleshooting strategies.

• Cyanine 3-dCTP (SKU B8159): Reliable Fluorescent DNA Labelin

  2026-07-21

  This article provides an evidence-driven guide for biomedical researchers and lab technicians tackling challenges in direct enzymatic DNA and cDNA labeling. Using 'Cyanine 3-dCTP' (SKU B8159), we examine reproducibility, sensitivity, protocol optimization, and vendor reliability—grounded in data, peer-reviewed literature, and real-world laboratory scenarios.

• Applied Insights: Puromycin Aminonucleoside in Podocyte Inju

  2026-07-21

  Puromycin aminonucleoside is the gold-standard reagent for inducing nephrotic syndrome and podocyte injury in experimental models, enabling mechanistically faithful studies of glomerular pathology. This guide translates bench protocols, troubleshooting strategies, and new mechanistic findings into actionable workflows, maximizing the impact of APExBIO’s high-purity compound in renal research.

• Super-Enhancer Hijacking of LINC01977 in Early Lung Adenocar

  2026-07-20

  Zhang et al. (2022) uncovered a mechanism in early-stage lung adenocarcinoma where a super-enhancer hijacks the lncRNA LINC01977, amplifying tumor aggressiveness via the TGF-β/SMAD3 axis. These findings highlight new epigenetic vulnerabilities and suggest that targeting transcriptional coactivators may present valuable research opportunities in cancer biology.

• Müller Cell PEDF and Angiopoietin Signaling in Retinal Neuro

  2026-07-20

  This study establishes that Müller cell-derived pigment epithelium-derived factor (PEDF) is a critical modulator of retinal neuron survival via angiopoietin-dependent Tie-2 signaling. The findings clarify how Ang-1 and Ang-2 differentially regulate neuroprotective and angiogenic pathways, revealing new molecular targets for retinal neuroprotection and anti-angiogenic intervention.

• Refining In Vitro Drug Response Metrics for Cancer Research

  2026-07-19

  Schwartz’s dissertation introduces a dual-metric framework that distinguishes between proliferative arrest and cell death when evaluating anti-cancer drugs in vitro. This nuanced approach challenges the field’s reliance on single-parameter assays, offering researchers improved tools for dissecting drug effects and guiding rational therapeutic development.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Cancer Mo

  2026-07-18

  Erlotinib (NSC 718781) enables precise dissection of EGFR-driven oncogenic signaling and resistance mechanisms in translational cancer research. This guide details optimized workflows, troubleshooting strategies, and actionable insights to maximize reproducibility and performance in EGFR pathway inhibition studies.

• Dimethyloxalylglycine (DMOG): Technical Use & Protocol Guide

  2026-07-17

  Dimethyloxalylglycine (DMOG) is a cell-permeable PHD inhibitor for stabilizing hypoxia-inducible factors in controlled research settings. It is suited for in vitro and in vivo modeling of hypoxia-related signaling and inflammation, but is not intended for diagnostic or clinical use. Researchers must observe solubility, storage, and workflow limits for reproducible results.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-07-17

  This study introduces a patient-specific gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, effectively recapitulating the cellular and molecular complexity of primary tumors. The approach enables improved drug response prediction and supports mechanistic studies of tumor–stroma interactions, with significant implications for personalized cancer therapy.

• Intravesical p21 mRNA-LNP: Localized Tumor Suppressor Therap

  2026-07-16

  Zeng et al. (2026) introduce a localized, non-viral approach to restore tumor suppressor function in bladder cancer by intravesical delivery of p21 mRNA-loaded lipid nanoparticles. Their findings demonstrate robust tumor inhibition and preservation of bladder architecture, advancing the translational promise of mRNA therapeutics for targeted, site-specific cancer treatment.

14727 records 1/982 page Next 12345 下5页 Last page